Compare SLVM & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLVM | DFTX |
|---|---|---|
| Founded | 1898 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2021 | N/A |
| Metric | SLVM | DFTX |
|---|---|---|
| Price | $38.90 | $18.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $54.00 | $40.25 |
| AVG Volume (30 Days) | 279.3K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $3,351,000,000.00 | N/A |
| Revenue This Year | $0.98 | N/A |
| Revenue Next Year | $2.28 | N/A |
| P/E Ratio | $12.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.52 | $14.62 |
| 52 Week High | $68.76 | $19.62 |
| Indicator | SLVM | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.93 | 55.19 |
| Support Level | $38.06 | $16.26 |
| Resistance Level | $46.59 | $19.62 |
| Average True Range (ATR) | 1.58 | 0.94 |
| MACD | -0.48 | -0.01 |
| Stochastic Oscillator | 1.62 | 55.05 |
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).